Literature DB >> 15552602

Oral isotretinoin in the treatment and prevention of cutaneous squamous cell carcinoma.

Evan Jones1, Adam Korzenko, David Kriegel.   

Abstract

The clinical uses of oral isotretinoin (13-cis-retinoic acid) are many. They include treatment of acneiform eruptions, diseases of cornification, inflammatory disorders, and neoplastic processes. Isotretinoin has shown greater efficacy in the chemoprevention of squamous cell carcinoma, rather than in the treatment. High-dose isotretinoin has mainly been utilized in those patients at high-risk for multiple new skin cancers where the risk of morbidity from side effects is overshadowed by the benefit to the patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15552602

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

1.  An apparently untreatable ulcer of the face.

Authors:  Alessandro Borghi; Sergio Gianesini; Massimo Pedriali; Antonio Stefanelli; Giovanni Mangiola; Patrizia Dalla Caneva; Giovanni Lanza; Annarosa Virgili; Paolo Zamboni
Journal:  Int Wound J       Date:  2016-01-10       Impact factor: 3.315

Review 2.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

3.  Isotretinoin and FoxO1: A scientific hypothesis.

Authors:  Bodo C Melnik
Journal:  Dermatoendocrinol       Date:  2011-07-01

Review 4.  Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians.

Authors:  Elisabeth Chroni; Alexandra Monastirli; Dionysios Tsambaos
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

Review 5.  Current Therapeutic Strategies of Xeroderma Pigmentosum.

Authors:  Mozammel Hossain; Ashraful Hasan; Mohammad Mahfuz Ali Khan Shawan; Subrata Banik; Iffat Jahan
Journal:  Indian J Dermatol       Date:  2021 Nov-Dec       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.